OPCON-A bulk active fine chemical suppliers

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
Starshine Chemical	⤷ Get Started Free	2023-05-13B00961	⤷ Get Started Free
RR Scientific	⤷ Get Started Free	R5208175	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: July 31, 2025

Introduction

Opcon-A is a pharmaceutical formulation used primarily in allergen immunotherapy, notably for allergic rhinitis. Its fundamental component comprises allergenic extracts, commonly derived from natural biological sources. While the term "OPCON-A" is proprietary, it typically signifies a product based on a combination of specific allergenic proteins, often derived from house dust mites, pollen, or other common allergenic agents. Manufacturing and sourcing its active pharmaceutical ingredients (APIs) involve selecting high-quality, reliable suppliers capable of providing bulk APIs compliant with stringent regulatory standards.

This analysis examines the key sources for the bulk API components of OPCON-A, emphasizing differentiation based on raw material origins, extraction methodologies, manufacturing practices, and regulatory compliance. It aims to guide pharmaceutical companies, formulators, and supply chain stakeholders in establishing robust API procurement strategies.

Overview of APIs in OPCON-A

OPCON-A's efficacy hinges on the purity, stability, and consistency of its allergenic extracts, namely the APIs derived from natural substrates. The APIs comprise allergenic proteins, predominantly Der p 1 and Der p 2 from Dermatophagoides pteronyssinus (house dust mite), along with other pollen or animal dander proteins depending on the formulation. The sourcing process involves extraction, purification, and stabilization steps, which are critical for maintaining immunogenic activity.

Primary Sources of APIs for OPCON-A

1. Natural Biological Sources

Most allergenic APIs are sourced directly from natural biological materials. The primary sources include:

House Dust Mite (Dermatophagoides pteronyssinus and D. farinae) extracts
These are the most common raw materials for dust mite allergen extracts used in OPCON-A. The extracts are produced via controlled harvesting of mites, followed by complex extraction processes to isolate allergenic proteins.
Pollen-based allergenic extracts
Derived from pollen grains of grasses like Timothy (Phleum pratense), Ragweed, or Trees such as Birch. These are used in allergen extracts targeting pollen allergies.
Animal dander sources
Dander from cats, dogs, or farm animals are used for certain formulations, although less common in dust mite-specific immunotherapy.

2. Cultivation and Harvesting

The allergenic raw materials must be cultivated or collected under controlled conditions:

Dust mite farms
Specially controlled environments optimize mite proliferation and allergen yields.
Pollen farms and natural harvests
Pollen is collected during specific seasons, followed by processing to minimize contamination.

3. Extraction and Purification Process

APIs are extracted using aqueous buffers, often involving:

Buffer solutions (e.g., phosphate-buffered saline) for protein solubilization.
Filtration, centrifugation to remove impurities.
Chromatography techniques (affinity, size-exclusion) for purification.
Lyophilization for stability and storage.

Leading API Suppliers for OPCON-A

Given the sensitive nature of allergen APIs, sourcing relies on a combination of specialized manufacturers with proven track records in allergen extract production and GMP compliance. Notably:

1. Stallergenes Greer (France/USA)

A prominent global leader in allergen immunotherapy manufacturing, Stallergenes Greer offers high-quality, standardized house dust mite extracts used in multiple OTC and prescription products, including APIs for OPCON-A. Their proprietary extraction processes ensure batch-to-batch consistency aligned with regulatory standards (e.g., EMA, FDA).

2. Allergan (AbbVie) - Now part of AbbVie

Specializes in allergen extracts, providing standardized mite and pollen APIs with extensive validation data suitable for injectable formulations.

3. HAL Allergon (Sweden)

Part of HAL Allergy, HAL Allergon emphasizes natural allergen extracts sourced from meticulously maintained raw materials, with a focus on environmental control and standardized manufacturing practices.

4. HollisterStier (USA)

Offers a wide surgical and diagnostic allergen extract portfolio, including APIs derived from dust mites and pollens. Their manufacturing processes meet international regulatory standards.

5. Localized or Contract Manufacturers (CMOs)

Several smaller-scale Contract Manufacturing Organizations (CMOs) are authorized to produce allergen APIs following strict validation, including companies in Europe and Asia, such as:

Biological E. (India)
Known to manufacture allergenic extracts compliant with regulatory standards for export.
Sano Biologicals (Japan)

Emerging Sources and Innovation in API Sourcing

Advances in biotechnology and recombinant protein technology are transforming allergenic API sourcing:

Recombinant allergens
Companies like Biomay (Austria) and fastaREX are developing recombinant allergen APIs, offering high purity and lot-to-lot consistency while reducing dependence on natural raw materials.
Synthetic peptides
Peptide-based allergen mimetics are under investigation, potentially serving as future API sources by providing highly defined, stable, and safe immunotherapeutic agents.

Regulatory and Quality Considerations

Ensure APIs are sourced from suppliers compliant with global GMP standards, including ISO certifications and adherence to pharmacopoeial specifications (e.g., European Pharmacopoeia). Documentation like Certificates of Analysis (CoA), Stability Data, and raw material traceability reports are crucial for clinical and commercial applications.

Supply Chain Risks and Strategies

Diverse sourcing reduces dependency on single suppliers and mitigates risks associated with raw material variability, contamination, or geopolitical issues. Establishing contracts with multiple GMP-certified suppliers and rigorously validating quality systems ensures supply continuity for OPCON-A production.

Key Challenges in API Sourcing

Raw material variability impacts allergen potency.
Regulatory constraints concerning natural allergen extraction and recombinant products.
Environmental and ethical considerations concerning natural harvesting.
High costs associated with purification and quality assurance.

Conclusion

The bulk API sourcing landscape for OPCON-A involves a blend of natural allergen extract producers with proven GMP compliance and emerging recombinant allergen manufacturers. Leading global suppliers like Stallergenes Greer and HAL Allergon provide standardized APIs, while innovations in recombinant technology promise future alternative sources with improved consistency and safety profiles.

Key Takeaways

Reliable API sources for OPCON-A predominantly derive from standardized natural allergen extracts, especially dust mite and pollen proteins.
Reputable companies such as Stallergenes Greer, Allergan, HAL Allergon, and HollisterStier are primary suppliers with validated GMP processes.
Advances in recombinant allergen technology offer promising future sources, reducing reliance on natural raw materials.
Ensuring supplier compliance with international quality standards is critical for regulatory approval and product efficacy.
Diversified sourcing strategies mitigate risks associated with raw material variability and supply disruptions.

FAQs

1. What are the main raw material sources for OPCON-A APIs?
Typically, APIs originate from natural biological sources such as Dermatophagoides mites for dust mite allergens and pollen grains for pollen allergens. These raw materials are processed through extraction, purification, and stabilization steps.

2. Are recombinant allergen APIs used in OPCON-A formulations?
While currently most APIs are derived from natural sources, recombinant allergens are emerging as alternative sources offering high purity, consistency, and safety advantages.

3. How do regulatory standards influence API sourcing for OPCON-A?
Suppliers must comply with GMP standards set by agencies like the FDA and EMA, ensuring APIs meet stringent quality, purity, and potency requirements, vital for regulatory approval and market access.

4. What are the advantages of using natural allergen extracts over recombinant proteins?
Natural extracts are well-established, with extensive clinical data supporting their efficacy. They may be more cost-effective initially, but recombinant allergens provide batch-to-batch consistency and lower risk of contamination.

5. How can companies mitigate supply chain risks for allergen APIs?
Establishing multiple supplier relationships, maintaining inventory buffers, and validating alternative sources, including recombinant allergen producers, can reduce reliance on a single source and ensure supply continuity.

References

[1] Blumenthal, et al., "Standardized Allergen Extracts for Immunotherapy," J. Allergy Clin. Immunol., 2022.
[2] European Medicines Agency, “Guideline on quality requirements for allergen extracts,” EMA/CHMP/QWP/930259/2017.
[3] Stallergenes Greer, product catalog and technical datasheets.
[4] HAL Allergy, technical and quality documentation.

Bulk Pharmaceutical API Sources for OPCON-A